• news.cision.com/
  • CLS/
  • Senior executives and larger owner exercise, pro rata, warrants of series TO 6 B for approximately SEK 0.7 million.
English

Senior executives and larger owner exercise, pro rata, warrants of series TO 6 B for approximately SEK 0.7 million.

Report this content

Lund, Sweden - Clinical Laserthermia Systems AB ("CLS" or the "Company") announces that senior executives and a larger owner exercise, pro rata, warrants of series TO 6 B for approximately SEK 0.7 million. The exercise period for the warrants of TO 6 B began on January 23, 2024 and continues until February 6, 2024. The last day of trading in warrants of series TO 6 B is February 2, 2024.

Senior executives and a larger owner in CLS (directly or through companies), as described below, exercise, pro rata, warrants of series TO 6 B for a total of approximately SEK 0.7 million:

 

  • Hans von Celsing (Chairman) – 800,000 TO 6 B, corresponding to approx. SEK 80 thousand
  • Dan J Mogren (CEO) – 315,960 TO 6 B, corresponding to approx. SEK 31.6 thousand
  • Khattar Holdings Pte Ltd – 5,952,375 TO 6 B, corresponding to approx. SEK 595 thousand

In order for the warrants not to expire worthless, the holder must subscribe for new B-shares, with the support of warrants, no later than 17:00 CET on February 6, 2024, or alternatively sell warrants no later than February 2, 2024.

 

Information brochures about the Company and the offer (in Swedish and English) and other material for investors are available on CLS, Sedermera Corporate Finance AB's, Redeye AB's and Nordic Issuing AB's respective websites (www.clinicallaser.se, www.sedermera.se, www.redeye.se, www.nordic-issuing.se). Complete terms and conditions and instructions for warrants of series TO 6 B are available on the Company's website.


Advisors

In connection with the exercise of warrants of series TO 6 B, Sedermera Corporate Finance AB and Redeye AB are Joint Lead Managers. Markets & Corporate Law Nordic AB is legal advisor and Nordic Issuing AB acts as issuing agent.

 

For more information about the warrants of series TO 6 B, please contact:

Sedermera Corporate Finance AB

Phone: +46 40 615 14 10

E-mail: cf@sedermera.se

Website: www.sedermera.se

 

Redeye AB

Phone: +46 (0)8 545 013 30

E-mail: info@redeye.se

Website: www.redeye.se

 

For more information about CLS, please contact:

Dan J Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com

Website: www.clinicallaser.se

 

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

 

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.

 

For more information about CLS, please visit the Company's website: www.clinicallaser.se

 

Subscribe

Documents & Links